HAYA raises $65 million to ‘unlock the dark genome’s therapeutic potential’

Switzerland-based HAYA Therapeutics, a biotech developing precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, has raised $65 million in a Series A funding round.

The financing will accelerate the clinical development of HAYA’s lead long non-coding RNA (lncRNA) targeting candidate, HTX-001, in heart failure, and the continued expansion of its RNA-guided regulatory genome pipeline development engine. 

Management has said that the support emphasizes investor confidence in HAYA’s ground-breaking science and positions the company to deliver on its mission of bringing disease-modifying, precision medicines faster and more efficiently to patients.